Literature DB >> 22640757

Advances in opioid antagonist treatment for opioid addiction.

Walter Ling1, Larissa Mooney, Li-Tzy Wu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22640757      PMCID： PMC4178977          DOI： 10.1016/j.psc.2012.03.002

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN： 0193-953X


× No keyword cloud information.
  36 in total

1.  Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement.

Authors:  K M Carroll; S A Ball; C Nich; P G O'Connor; D A Eagan; T L Frankforter; E G Triffleman; J Shi; B J Rounsaville
Journal:  Arch Gen Psychiatry       Date:  2001-08

2.  An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.

Authors:  R B Rothman; D A Gorelick; S J Heishman; P R Eichmiller; B H Hill; J Norbeck; J G Liberto
Journal:  J Subst Abuse Treat       Date:  2000-04

3.  Naltrexone plus benzodiazepine aids abstinence in opioid-dependent patients.

Authors:  Luigi Stella; Ciro D'Ambra; Filomena Mazzeo; Annalisa Capuano; Francesco Del Franco; Amalia Avolio; Francesco Ambrosino
Journal:  Life Sci       Date:  2005-10-07       Impact factor: 5.037

4.  Naltrexone and buprenorphine combination in the treatment of opioid dependence.

Authors:  G Gerra; A Fantoma; A Zaimovic
Journal:  J Psychopharmacol       Date:  2006-01-09       Impact factor: 4.153

5.  Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials Network.

Authors:  Li-Tzy Wu; Walter Ling; Bruce Burchett; Dan G Blazer; Chongming Yang; Jeng-Jong Pan; Bryce B Reeve; George E Woody
Journal:  Drug Alcohol Depend       Date:  2011-04-17       Impact factor: 4.492

6.  Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex.

Authors:  Vishala L Chindalore; Richard A Craven; K Peony Yu; Peter G Butera; Lindsay H Burns; Nadav Friedmann
Journal:  J Pain       Date:  2005-06       Impact factor: 5.820

7.  Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Authors:  Evgeny Krupitsky; Edward V Nunes; Walter Ling; Ari Illeperuma; David R Gastfriend; Bernard L Silverman
Journal:  Lancet       Date:  2011-04-30       Impact factor: 79.321

8.  Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate.

Authors:  T J Gan; B Ginsberg; P S Glass; J Fortney; R Jhaveri; R Perno
Journal:  Anesthesiology       Date:  1997-11       Impact factor: 7.892

9.  A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.

Authors:  Elmer Yu; Karen Miotto; Evaristo Akerele; Ann Montgomery; Ahmed Elkashef; Robert Walsh; Ivan Montoya; Marian W Fischman; Joseph Collins; Frances McSherry; Kathy Boardman; David K Davies; Charles P O'Brien; Walter Ling; Herbert Kleber; Barbara H Herman
Journal:  Drug Alcohol Depend       Date:  2008-05-27       Impact factor: 4.492

10.  Pharmacological enhancement of naltrexone treatment for opioid dependence: a review.

Authors:  Paolo Mannelli; Kathleen S Peindl; Li-Tzy Wu
Journal:  Subst Abuse Rehabil       Date:  2011-06
View more
  6 in total

1.  Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.

Authors:  Edward V Nunes; Adam Bisaga; Evgeny Krupitsky; Narinder Nangia; Bernard L Silverman; Sarah C Akerman; Maria A Sullivan
Journal:  Addiction       Date:  2019-08-04       Impact factor: 6.526

2.  Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.

Authors:  Heide Jackson; Kara Mandell; Kimberly Johnson; Debanjana Chatterjee; David J Vanness
Journal:  Subst Abus       Date:  2015-03-16       Impact factor: 3.716

3.  Changes in fentanyl demand following naltrexone, morphine, and buprenorphine in male rats.

Authors:  Lindsey R Hammerslag; Rebecca S Hofford; Qiwen Kang; Richard J Kryscio; Joshua S Beckmann; Michael T Bardo
Journal:  Drug Alcohol Depend       Date:  2019-12-16       Impact factor: 4.492

4.  Factors associated with willingness to take extended release naltrexone among injection drug users.

Authors:  Keith Ahamad; M J Milloy; Paul Nguyen; Sasha Uhlmann; Cheyenne Johnson; Todd P Korthuis; Thomas Kerr; Evan Wood
Journal:  Addict Sci Clin Pract       Date:  2015-05-03

Review 5.  Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine.

Authors:  Florence Noble; Nicolas Marie
Journal:  Front Psychiatry       Date:  2019-01-18       Impact factor: 4.157

Review 6.  Retention Strategies for Medications for Opioid Use Disorder in Adults: A Rapid Evidence Review.

Authors:  Brian Chan; Emily Gean; Irina Arkhipova-Jenkins; Jennifer Gilbert; Jennifer Hilgart; Celia Fiordalisi; Kimberly Hubbard; Irene Brandt; Elizabeth Stoeger; Robin Paynter; Philip Todd Korthuis; Jeanne-Marie Guise
Journal:  J Addict Med       Date:  2021 Jan-Feb 01       Impact factor: 4.647
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.